H.I.G. Capital News

ForSight VISION5 Appoints Hector Casab Vice President of Finance

MENLO PARK, CA - July 9, 2015 - ForSight VISION5 announced today the appointment of senior finance executive Hector Casab as Vice President of Finance, effective July 13, 2015.

Mr. Casab joins ForSight VISION5 from ophthalmic pharmaceutical company Icon Bioscience, Inc., where as Vice President of Finance and Administration he oversaw all aspects of finance, operations, and administration. Key achievements included the implementation of a new financial management infrastructure and the successful transfer of drug product manufacturing and testing from the company’s research lab to a commercial-scale cGMP site.

Mr. Casab was previously Senior Director, Financial Planning and Analysis, at Onyx Pharmaceuticals, Inc., providing financial management and leadership during Onyx’s rapid growth leading up to its acquisition by Amgen. During his five-plus year tenure at Genentech, Mr. Casab’s multiple roles included Director, Corporate Planning, Director, Global Supply Chain Finance, and Associate Director, Manufacturing Collaborations Finance. He was previously with Applied Biosystems, serving in various roles in operations and finance.

“Hector is a strong addition to ForSight VISION5, with a solid track record in successfully increasing shareholder value,” said John Maroney, president and chief executive officer. “Hector brings a wealth of strategic and executional experience that will benefit the company as we continue to advance development of our pipeline, including the Helios™ insert, our novel, non-invasive delivery system designed for continuous delivery of medication to glaucoma and ocular hypertensive patients. I am pleased to welcome him to the ForSight VISION5 team.”

Mr. Casab holds an M.B.A. from Santa Clara University with a concentration in Marketing and Finance, and a B.S. from Oakland University in Accounting and Management Information Systems.

About ForSight VISION5, Inc
ForSight VISION5, Inc. was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC. ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5’s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. ForSight VISION5’s investors include Versant Ventures, Morgenthaler Ventures, Technology Partners, Delphi Ventures, and H.I.G. BioVentures. For more information, please visit www.forsightvision5.com.